Latest Carcinoma Stories

Multicentric carcinogenesis with the same genetic mutation appears to occur in lung adenocarcinoma, according to data presented at the AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer: Biology, Therapy and Personalized Medicine, held Jan. 8-11, 2012. Data also demonstrated that the EGFR and KRAS genes, which are mutually exclusive, can be used to define clinically relevant molecular subsets of lung adenocarcinoma and can define tumor clonality. "The information on genetic...

(Ivanhoe Newswire) – Papillary carcinoma is the most common type of thyroid cancer, and about one fourth of these carcinomas have mutations in the BRAF gene. These mutations are most common in high-grade carcinomas, in particular, the ones that resist standard treatments. According to researchers at Memorial Sloan-Kettering Cancer Center, New York, exploiting the expression of BRAF by the resistant cancers could be a therapeutic advantage. Despite the prevalence of BRAF mutations in...

Papillary carcinoma is the most common form of thyroid cancer. Approximately one quarter of these carcinomas have mutations in the BRAF gene. The prevalence of such mutations is even greater in high-grade carcinomas, particularly those that are refractory to standard treatment, which is radioactive iodine (RAI). A team of researchers led by James Fagin, at Memorial Sloan-Kettering Cancer Center, New York, has now identified a way to potentially exploit the expression of BRAF by such cancers...

A recent report in Cancer Discovery, a journal of the American Association for Cancer Research, suggests that a new treatment may be on the horizon for neuroendocrine prostate cancers, the most lethal subtype of this disease. Mark Rubin, M.D., professor of pathology and laboratory medicine at Weill Cornell Medical College, said although fewer than 2 percent of men with prostate cancer present with neuroendocrine prostate cancer, the more common prostate adenocarcinoma can also evolve into...

Researchers confirmed an association between tanning bed use and an increased risk for three common skin cancers — basal cell carcinoma, squamous cell carcinoma and melanoma, according to results presented at the 10th AACR International Conference on Frontiers in Cancer Prevention Research, held Oct. 22-25, 2011. The popularity of indoor tanning is widespread, with roughly 10 percent of Americans using a tanning facility each year. However, use of tanning beds has been shown to be...

The nature of the connective tissue surrounding lung cancer nests can help predict the aggressiveness of squamous cell carcinoma, according to research published in the September issue of the Journal of Thoracic Oncology, the official publication of the International Association for the Study of Lung Cancer (IASLC). Non-small cell lung cancer (NSCLC) is the major cause of cancer-related deaths worldwide; its two major subtypes are adenocarcinoma and squamous cell carcinoma (SqCC). Although...

Study published in The American Journal of Pathology The first report of the presence of alternative lengthening of telomeres (ALT) in cancers arising from the bladder, cervix, endometrium, esophagus, gallbladder, liver, and lung was published today in The American Journal of Pathology. The presence of ALT in carcinomas can be used as a diagnostic marker and has implications for the development of anti-cancer drug therapies. Telomeres are nucleoprotein complexes located at the ends of...

BOCA RATON, Fla., July 28, 2011 /PRNewswire/ -- Sensus Healthcare is pleased to announce that the Prince of Wales Hospital in Hong Kong has become the first healthcare facility in the country to purchase and deploy an SRT-100(TM) non-invasive skin cancer treatment system. The SRT-100(TM) will provide the local patient community with the most effective, non-surgical, and pain free therapy modality to treat non-Melanoma Basal and Squamous Cell skin cancers, which account for the vast majority...

SAN DIEGO, July 28, 2011 /PRNewswire/ -- Polaris Group (Polaris) today announced that it has dosed the first patient in a pivotal Phase 3 clinical trial evaluating its lead cancer therapeutic, pegylated arginine deiminase (ADI-PEG 20), in hepatocellular carcinoma (HCC) patients. Over 600 patients who have failed prior systemic therapy will be enrolled in the randomized, double-blind, placebo-controlled study at sites in China, Taiwan, the United States, Italy and the U.K.. Patients will...

(Ivanhoe Newswire) "“ A key for early diagnosis of cancer and personalized medicine is the order of genetic aberrations - deviations or irregularity - in individual cancers. Now, scientists have begun to reveal the order of mutations that lead to cancer."We know that each cancer is a collection of genetic malfunctions," Raymond Cho, Ph.D., assistant clinical professor in the department of dermatology at the University of California, San Francisco, was quoted as saying."We now...